Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Common Equity (2016 - 2025)

Lipocine (LPCN) has disclosed Common Equity for 13 consecutive years, with $14.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity fell 26.02% year-over-year to $14.1 million, compared with a TTM value of $14.1 million through Sep 2025, down 26.02%, and an annual FY2024 reading of $21.0 million, up 3.08% over the prior year.
  • Common Equity was $14.1 million for Q3 2025 at Lipocine, down from $17.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $45.6 million in Q4 2021 and bottomed at $14.1 million in Q3 2025.
  • Average Common Equity over 5 years is $29.0 million, with a median of $28.6 million recorded in 2023.
  • The sharpest move saw Common Equity surged 546.92% in 2021, then tumbled 42.84% in 2023.
  • Year by year, Common Equity stood at $45.6 million in 2021, then fell by 21.8% to $35.6 million in 2022, then crashed by 42.84% to $20.4 million in 2023, then rose by 3.08% to $21.0 million in 2024, then crashed by 32.65% to $14.1 million in 2025.
  • Business Quant data shows Common Equity for LPCN at $14.1 million in Q3 2025, $17.1 million in Q2 2025, and $19.2 million in Q1 2025.